PRM-151 for Idiopathic Pulmonary Fibrosis

Marta Ribeiro avatar

by Marta Ribeiro |

Share this article:

Share article via email

pf_prm

PRM-151 is a recombinant human serum amyloid P/pentraxin 2 protein developed by Promedior, a biotechnology company developing therapies for fibrotic diseases using plasma-derived proteins and peptides. Also referred to as PTX2, the therapy is injected intravenously in patients and is showing promise as an effective anti-fibrotic agent which can be used to target several rare orphan diseases with unmet therapeutic needs.

Promedior is currently focusing on rare systemic fibrotic diseases and their prime targets include idiopathic pulmonary fibrosis (IPF), myelofibrosis and retinal fibrovascular diseases.

Read more about it: http://bit.ly/1XVGFjZ

Print This Page

About the Author

Marta Ribeiro avatar
Marta Ribeiro Marta graduated from Universidade Fernando Pessoa in Porto with a degree in Communication Sciences and a Masters degree in New Communication Technologies. She has experience in social media, worked with several media channels, and has also worked as a freelance photographer and a graphic artist for almost 10 years.

Tags

Idiopathic pulmonary fibrosis (IPF), IPF, PRM-151, pulmonary fibrosis

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums

Recent Posts


Recommended reading